Saikosaponin A alleviates glycolysis of breast cancer cells through repression of Akt/STAT3 pathway
Chemical Biology & Drug Design · 2023
DOI: 10.1111/cbdd.14259 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2023. Verfasst von Yan Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Research, Shinshu University School of Medicine, Matsumoto, Japan. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Saikosaponin A (SSA) has been revealed to have anti‐breast cancer (BC) effect. However, the association between SSA and BC glycolysis is obscure. We want to probe the function and mechanism of SSA on BC glycolysis. Kaplan–Meier plotter revealed the relationship between STAT3 and the survival curve of BC. The protein kinase B (Akt)/signal transducer and activator of transcription 3 (STAT3) pathway and the viability in cells treated with or without 0, 5, 10, and 15 μM SSA were assessed by Western blot and cell counting kit‐8. The biological behaviors, lactate, and ATP contents, glucose uptake, and Akt/STAT3 pathway‐related markers in BC cells treated with colivelin or SSA were evaluated using cell function experiments, kit, and Western blot. Then, the impacts of colivelin and SSA on BC cells were tested again. The overexpressions of p‐STAT3 and p‐Akt in BC cells were weakened by 5, 10, and 15 μM SSA. Colivelin boosted the BC cell viability and proliferation and impeded apoptosis, while SSA did the opposite. Meanwhile, colivelin intensified lactate and ATP contents, glucose uptake, and Akt/STAT3 pathway‐related markers level in BC cells, while SSA was the opposite. The modulation of SSA on the biological behavior, lactate and ATP productions, glucose uptake, and Akt/STAT3 pathway was rescued by colivelin. Our research unveiled new insights into SSA as a valuable candidate therapeutic agent for weakening glycolysis, and protruded the Akt/STAT3 pathway as a latent molecular target for SSA and glycolysis modulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Research, Shinshu University School of Medicine, Matsumoto, Japan.
- Medical Department, Minghui Pharmaceutical (Shanghai) Co. Ltd., Shanghai, China.
- Department of Neurosurgery, The Second Affiliated Hospital of Hainan Medical University, Haikou, China.
- Scientific Research Section, The Second Affiliated Hospital of Hainan Medical University, Haikou, China.
- Department of Radiotherapy, The Second Affiliated Hospital of Hainan Medical University, Haikou, China.
- Weifang Business Vocational College, Weifang, China.
Zitieren
APA
Zhang, Y., Dai, K., Xu, D., Fan, H., Ji, N., Wang, D., Zhao, Y., & Liu, R. (2023). Saikosaponin A alleviates glycolysis of breast cancer cells through repression of Akt/STAT3 pathway. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14259
Vancouver
Zhang Y, Dai K, Xu D, Fan H, Ji N, Wang D, et al. Saikosaponin A alleviates glycolysis of breast cancer cells through repression of Akt/STAT3 pathway. Chemical Biology & Drug Design. 2023. doi:10.1111/cbdd.14259
BibTeX
@article{Zhang2023,
author = {Zhang, Yan and Dai, Kun and Xu, Dedong and Fan, Hua and Ji, Nannan and Wang, Di and Zhao, Yunlu and Liu, Rui},
title = {Saikosaponin A alleviates glycolysis of breast cancer cells through repression of Akt/STAT3 pathway},
journal = {Chemical Biology & Drug Design},
year = {2023},
doi = {10.1111/cbdd.14259}
}
EUVIMED